obesity
Page 3 of 12
By Orianna Rosa RoyleOctober 17, 2024
By Chris MorrisOctober 10, 2024
By Deena Shanker and BloombergOctober 2, 2024
FinanceNovo Nordisk’s $570 billion valuation is more than Denmark’s GDP—but PM isn’t worried about a ‘Nokia risk’
By Sara Sjolin, Sanne Wass, Oliver Crook and BloombergSeptember 23, 2024
By David Morris and BloombergSeptember 18, 2024
By Arthur Allen and KFF Health NewsAugust 7, 2024
RetailEurope’s most valuable company Novo Nordisk reports an uptick in profits as demand for weight-loss drugs continues to grow
By AFPAugust 7, 2024
CommentaryI’m an obesity medicine doctor and I’ve been on weight-loss drugs like Ozempic for a decade. Here’s why I think they aren’t a fad
By Angela FitchJuly 30, 2024
RetailAn obesity pill study tested on just 25 patients led to a stunning $16.8 billion increase in Swiss drugmaker Roche’s market value
By Naomi Kresge, Lisa Pham and BloombergJuly 23, 2024
By Lindsey LeakeJuly 18, 2024
HealthFake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs
By Amanda LoudinJune 27, 2024
HealthEU urges clampdown on cosmetic misuse of Novo’s Ozempic amid worsening drug shortages for diabetics
By Naomi Kresge and BloombergJune 26, 2024
Most Popular
